MA42145A - Triazoles agonistes du récepteur apj - Google Patents
Triazoles agonistes du récepteur apjInfo
- Publication number
- MA42145A MA42145A MA42145A MA42145A MA42145A MA 42145 A MA42145 A MA 42145A MA 42145 A MA42145 A MA 42145A MA 42145 A MA42145 A MA 42145A MA 42145 A MA42145 A MA 42145A
- Authority
- MA
- Morocco
- Prior art keywords
- formula
- triazoles
- apj receptor
- receptor agonist
- compounds
- Prior art date
Links
- 229940124752 APJ receptor agonist Drugs 0.000 title abstract 2
- 150000003852 triazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
L'invention concerne des composés de formule (i) et de formule (ii), les sels pharmaceutiquement acceptables de ceux-ci, des stéréo-isomères de l'un quelconque des éléments précités, ou des mélanges de ceux-ci, qui sont des agonistes du récepteur apj et sont utiles dans le traitement de maladies cardiovasculaires et d'autres troubles. Les composés de formule (i) et de formule (ii) présentent les structures suivantes : dans ces structures, les définitions des variables se trouvent dans la description.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562164106P | 2015-05-20 | 2015-05-20 | |
PCT/US2016/033088 WO2016187308A1 (fr) | 2015-05-20 | 2016-05-18 | Triazoles agonistes du récepteur apj |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42145A true MA42145A (fr) | 2018-04-04 |
MA42145B1 MA42145B1 (fr) | 2020-05-29 |
Family
ID=56134572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42145A MA42145B1 (fr) | 2015-05-20 | 2016-05-18 | Triazoles agonistes du récepteur apj |
Country Status (38)
Country | Link |
---|---|
US (10) | US9573936B2 (fr) |
EP (1) | EP3300500B9 (fr) |
JP (3) | JP6356364B1 (fr) |
KR (1) | KR102653667B1 (fr) |
CN (1) | CN108137545B (fr) |
AR (1) | AR104716A1 (fr) |
AU (1) | AU2016263564B2 (fr) |
BR (1) | BR112017024618B1 (fr) |
CA (1) | CA2985542C (fr) |
CL (1) | CL2017002922A1 (fr) |
CO (1) | CO2017012991A2 (fr) |
CY (1) | CY1123451T1 (fr) |
DK (1) | DK3300500T3 (fr) |
EA (1) | EA034776B1 (fr) |
ES (1) | ES2791315T3 (fr) |
HK (1) | HK1253366A1 (fr) |
HR (1) | HRP20200690T1 (fr) |
HU (1) | HUE050317T2 (fr) |
IL (1) | IL255459A (fr) |
JO (1) | JO3653B1 (fr) |
LT (1) | LT3300500T (fr) |
MA (1) | MA42145B1 (fr) |
ME (1) | ME03733B (fr) |
MX (1) | MX2017014818A (fr) |
MY (1) | MY193818A (fr) |
NZ (1) | NZ737004A (fr) |
PE (1) | PE20180529A1 (fr) |
PH (1) | PH12017502107A1 (fr) |
PL (1) | PL3300500T3 (fr) |
PT (1) | PT3300500T (fr) |
RS (1) | RS60353B1 (fr) |
SI (1) | SI3300500T1 (fr) |
TN (1) | TN2017000483A1 (fr) |
TW (1) | TWI606039B (fr) |
UA (1) | UA119932C2 (fr) |
UY (1) | UY36684A (fr) |
WO (1) | WO2016187308A1 (fr) |
ZA (1) | ZA201707706B (fr) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1143120A (ja) * | 1997-07-28 | 1999-02-16 | Ishikawajima Harima Heavy Ind Co Ltd | 容器の後処理装置 |
MA42145B1 (fr) * | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
EP3303330B1 (fr) | 2015-06-03 | 2019-05-01 | Bristol-Myers Squibb Company | Agonistes d'apj 4-hydroxy-3-(hétéroaryl)pyridine-2-one à utiliser dans le traitement de troubles cardio-vasculaires |
PE20181197A1 (es) | 2015-10-14 | 2018-07-23 | Bristol Myers Squibb Co | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) |
ES2895124T3 (es) | 2016-03-24 | 2022-02-17 | Bristol Myers Squibb Co | 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonistas de APJ |
US9988369B2 (en) | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
WO2018093577A1 (fr) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Composés de triazole à substitution cycloalkyle en tant qu'agonistes du récepteur apj |
MA46824A (fr) | 2016-11-16 | 2019-09-25 | Amgen Inc | Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj |
WO2018097944A1 (fr) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Composés de triazole furane utilisés en tant qu'agonistes du récepteur apj |
WO2018097945A1 (fr) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazoles substitués par hétéroaryle utilisés en tant qu'agonistes du récepteur apj |
US10906890B2 (en) | 2016-11-16 | 2021-02-02 | Amgen Inc. | Triazole phenyl compounds as agonists of the APJ receptor |
EP3541803B1 (fr) * | 2016-11-16 | 2020-12-23 | Amgen Inc. | Composés de triazole pyridyle en tant qu'agonistes du récepteur apj |
SG11202001112RA (en) * | 2017-08-15 | 2020-03-30 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
MA50509A (fr) | 2017-11-03 | 2021-06-02 | Amgen Inc | Agonistes de triazole fusionnés du récepteur apj |
EP3759095A1 (fr) | 2018-03-01 | 2021-01-06 | Annapurna Bio Inc. | Composés et compositions destinés au traitement d'états pathologiques associés à une activité du récepteur de l'apj |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
CN108795853B (zh) * | 2018-05-28 | 2021-08-24 | 天津博雅秀岩生物技术有限公司 | 制备犬胎膜间充质干细胞的方法和犬胎膜间充质干细胞 |
CN108728408B (zh) * | 2018-05-28 | 2021-08-24 | 天津博雅秀岩生物技术有限公司 | 犬胎膜间充质干细胞及制备方法和使用的培养基 |
CA3216236A1 (fr) * | 2021-04-06 | 2022-10-13 | BioAge Labs, Inc. | Modulateurs du recepteur de l'apeline de traitement de pathologies musculaires liees a l'age |
WO2024072907A1 (fr) | 2022-09-27 | 2024-04-04 | BioAge Labs, Inc. | Agonistes du récepteur de l'apeline pour le traitement d'états musculaires |
WO2024148104A1 (fr) | 2023-01-03 | 2024-07-11 | BioAge Labs, Inc. | Polythérapie d'agoniste du récepteur d'apeline et d'agoniste du récepteur de glp-1 pour le traitement d'une maladie ou d'une affection associée à une prise de poids |
CN117417325A (zh) * | 2023-12-19 | 2024-01-19 | 药康众拓(北京)医药科技有限公司 | 氘代1,2,4-***类Apelin受体激动剂药物及用途 |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US4681943A (en) * | 1984-11-30 | 1987-07-21 | The Dow Chemical Company | 1-acyl-1-(2-pyridinyl)semicarbazides |
JPS62149673A (ja) * | 1985-09-05 | 1987-07-03 | Sumitomo Chem Co Ltd | ピリジン誘導体、その製造法およびそれを有効成分とする植物病害防除剤 |
DE3825867A1 (de) | 1988-03-04 | 1989-09-14 | Bayer Ag | Heterocyclisch substituierte sulfonylaminoazole und ihre verwendung als herbizide |
EP0409332A3 (en) | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
DE3928605A1 (de) | 1989-08-30 | 1991-03-07 | Bayer Ag | Substituierte sulfonylaminoazole |
WO1991011909A1 (fr) | 1990-02-13 | 1991-08-22 | Merck & Co., Inc. | Antagonistes de triazole angiotensine ii incorporant un element de benzyle substitue |
JPH0511439A (ja) | 1990-09-13 | 1993-01-22 | Fuji Photo Film Co Ltd | 光重合性組成物 |
DE4035141A1 (de) | 1990-11-06 | 1992-05-07 | Bayer Ag | Substituierte sulfonylaminotriazolylpyrimidine |
SK278998B6 (sk) | 1991-02-01 | 1998-05-06 | Merck Sharp & Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu, spôsob i |
SE9103397D0 (sv) | 1991-11-18 | 1991-11-18 | Kabi Pharmacia Ab | Nya substituerade salicylsyror |
JP3217846B2 (ja) * | 1992-03-04 | 2001-10-15 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫剤 |
US5510362A (en) | 1992-03-13 | 1996-04-23 | Merck, Sharp And Dohme Limited | Imidazole, triazole and tetrazole derivatives |
US5411839A (en) | 1993-01-15 | 1995-05-02 | Eastman Kodak Company | Image formation in color reversal materials using strong inhibitors |
KR100441334B1 (ko) | 1995-02-03 | 2004-10-20 | 파마시아 앤드 업존 캄파니 | 헤테로-방향족고리치환된페닐옥사졸리딘온항균제 |
US5563026A (en) | 1995-04-28 | 1996-10-08 | Eastman Kodak Company | Color negative element having improved green record printer compatibility |
DE19725450A1 (de) | 1997-06-16 | 1998-12-17 | Hoechst Schering Agrevo Gmbh | 4-Haloalkyl-3-heterocyclylpyridine und 4-Haloalkyl-5-heterocyclylpyrimidine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
JP3788676B2 (ja) | 1997-11-11 | 2006-06-21 | 富士写真フイルム株式会社 | 有機エレクトロルミネツセンス素子材料およびそれを使用した有機エレクトロルミネツセンス素子 |
DE69902634T2 (de) | 1998-02-13 | 2003-04-24 | Pharmacia & Upjohn Co., Kalamazoo | Substituierte aminophenylisoxazolinderivate verwendbar als antimikrobielle agenzien |
AU3180999A (en) | 1998-02-25 | 1999-09-15 | Pharmacia & Upjohn Company | Substituted aminomethyl isoxazoline derivatives useful as antimicrobials |
SK4772002A3 (en) | 1999-09-10 | 2002-11-06 | Merck & Co Inc | Tyrosine kinase inhibitors, pharmaceutical composition containing the same and their use |
ATE362940T1 (de) | 2000-03-16 | 2007-06-15 | Genesoft Inc | Geladene verbindungen mit einer nukleinsäure- bindenden einheit sowie deren verwendungen |
CN1419563A (zh) | 2000-03-23 | 2003-05-21 | 武田药品工业株式会社 | 肽衍生物 |
EP1293503A4 (fr) | 2000-05-19 | 2008-04-02 | Astellas Pharma Inc | Derives de triazole |
WO2002053160A1 (fr) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Methode de traitement du glaucome ivb |
WO2002053101A2 (fr) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Procede de traitement de troubles fibrogenes et autres symptomes de type ivc |
MXPA03009846A (es) * | 2001-04-27 | 2004-05-05 | Vertex Pharma | Derivados de triazol inhibidores de cinasa y usos de los mismos. |
US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6727364B2 (en) | 2001-04-30 | 2004-04-27 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
US6790846B2 (en) | 2001-05-24 | 2004-09-14 | The Procter & Gamble Company | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity |
JP2003005356A (ja) | 2001-06-20 | 2003-01-08 | Fuji Photo Film Co Ltd | 電子線又はx線用ネガ型レジスト組成物 |
DE10138569A1 (de) | 2001-08-06 | 2003-04-30 | Bayer Ag | Regulation des APJ-Rezeptors |
JP2003321456A (ja) | 2002-04-30 | 2003-11-11 | Fuji Photo Film Co Ltd | 5−アミノ−4−含窒素芳香族ヘテロ環置換ピラゾール類の製造方法 |
EA009478B1 (ru) | 2002-08-23 | 2008-02-28 | Ардеа Байосайенсиз, Инк. | Ненуклеозидные ингибиторы обратной транскриптазы |
US7084145B2 (en) | 2002-10-25 | 2006-08-01 | Pfizer Inc. | Triazole compounds useful in therapy |
EP1581222A2 (fr) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | Compositions et procedes permettant d'inhiber le tgf-$g(b) |
US20040167188A1 (en) | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
WO2004078923A2 (fr) | 2003-02-28 | 2004-09-16 | Plexxikon, Inc. | Structure cristalline de pyk2 et ses utilisations |
WO2005004818A2 (fr) | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Composes heterocycliques et leur utilisation comme agents anticancereux |
ATE423122T1 (de) | 2003-08-15 | 2009-03-15 | Astrazeneca Ab | Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri) |
WO2005039569A1 (fr) | 2003-10-18 | 2005-05-06 | Bayer Healthcare Ag | Derives de 2-(phenylmethyl)thio-4-phenyl-4h-1,2,4-triazole substitues en 5 et composes associes utilises en tant que gaba-agonistes dans le traitement de l'incontinence urinaire et des maladies associees |
JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
US20050165015A1 (en) | 2004-01-23 | 2005-07-28 | Ncube Mghele V. | Vanilloid receptor ligands and their use in treatments |
US7297168B2 (en) | 2004-02-02 | 2007-11-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
AU2005230867A1 (en) | 2004-03-26 | 2005-10-20 | Amphora Discovery Corporation | Certain triazole-based compounds, compositions, and uses thereof |
US20080153869A1 (en) | 2004-06-14 | 2008-06-26 | Bressi Jerome C | Kinase Inhibitors |
US7399317B2 (en) | 2004-08-26 | 2008-07-15 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
CN101014578B (zh) | 2004-09-16 | 2011-01-19 | 安斯泰来制药有限公司 | ***衍生物或其盐 |
EP2298748B1 (fr) | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | Composés triazole modulant l'activité de HSP90 |
US20060156480A1 (en) | 2005-01-14 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
WO2006080533A1 (fr) | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | Dérivé de 3-amino-1,2,4-triazole |
EP1857446B1 (fr) | 2005-03-09 | 2013-05-01 | Nippon Kayaku Kabushiki Kaisha | Dérivés de 3-(2,4-dihydroxyphényl)-1,2,4-triazole utiles dans le traitement de cancer |
US8399464B2 (en) | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
JP2008533193A (ja) | 2005-03-21 | 2008-08-21 | ファイザー・リミテッド | オキシトシン拮抗薬としての置換トリアゾール誘導体 |
WO2006109817A1 (fr) | 2005-04-06 | 2006-10-19 | Banyu Pharmaceutical Co., Ltd. | Dérivé de substituée pipérazine en 1,4 |
WO2007007688A1 (fr) | 2005-07-08 | 2007-01-18 | Mochida Pharmaceutical Co., Ltd. | Dérivé de 3,5-diamino-1,2,4-triazole |
US7615569B2 (en) | 2005-08-16 | 2009-11-10 | Icagen, Inc. | Inhibitors of ion channels |
EP1917251B1 (fr) | 2005-08-21 | 2013-04-03 | Abbott GmbH & Co. KG | Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5 |
US8673848B2 (en) | 2012-01-27 | 2014-03-18 | Novartis Ag | Synthetic apelin mimetics for the treatment of heart failure |
CN101426766B (zh) | 2006-04-19 | 2014-03-26 | 默克雪兰诺有限公司 | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 |
PT2035396E (pt) | 2006-05-25 | 2014-07-29 | Synta Pharmaceuticals Corp | Compostos de triazol que modulam a atividade da hsp90 |
US8318790B2 (en) | 2006-05-25 | 2012-11-27 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
WO2007139952A2 (fr) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Synthèse de composés triazole modulant l'activité hsp90 |
TW200800260A (en) | 2006-05-25 | 2008-01-01 | Synta Pharmaceuticals Corp | Method for treating proliferative disorders associated with protooncogene products |
WO2007140002A2 (fr) | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Méthode pour traiter un lymphome non hodgkinien |
AU2012200157B2 (en) | 2006-05-25 | 2014-08-21 | Synta Pharmaceuticals Corp. | Method for treating proliferative disorders associated with protooncogene products |
US8778977B2 (en) | 2006-06-30 | 2014-07-15 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl PDK1 inhibitors |
US7718683B2 (en) | 2006-07-14 | 2010-05-18 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
JP5320291B2 (ja) | 2006-07-14 | 2013-10-23 | ケモセントリックス, インコーポレイテッド | トリアゾリルピリジルベンゼンスルホンアミド類 |
EP2054059A2 (fr) | 2006-08-17 | 2009-05-06 | Synta Pharmaceuticals Corporation | Composés de triazole modulant l'activité de la hsp90 |
US20110046125A1 (en) | 2006-10-19 | 2011-02-24 | Synta Pharmaceuticals Corp. | Method for treating infections |
US20100280032A1 (en) | 2006-10-26 | 2010-11-04 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
EP2118077B1 (fr) | 2007-02-08 | 2014-12-24 | Synta Pharmaceuticals Corp. | Composés à base de triazole modulant l'activité de hsp90 |
US7909187B2 (en) | 2007-02-20 | 2011-03-22 | Lonzell Montgomery | Modular baby bottle system |
WO2008112199A1 (fr) | 2007-03-12 | 2008-09-18 | Synta Pharmaceuticals Corp. | Procédé d'inhibition de la topoisomérase ii |
WO2008153730A2 (fr) | 2007-05-25 | 2008-12-18 | Synta Pharmaceuticals Corp. | Méthode de traitement des maladies prolifératives associées à des mutations dans c-met |
EP3173414A1 (fr) | 2007-07-17 | 2017-05-31 | ACEA Biosciences Inc. | Composés hétérocycliques et utilisations en tant qu'agents anticancéreux |
CA2695995C (fr) | 2007-08-13 | 2015-09-29 | Synta Pharmaceuticals Corp. | Composes de triazole qui modulent l'activite de hsp90 |
TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
WO2009075890A2 (fr) | 2007-12-12 | 2009-06-18 | Synta Pharmaceuticals Corp. | Composés triazole qui modulent l'activité de hsp90 |
WO2009085230A1 (fr) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibiteurs de la pi3 kinase |
DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
EP2103602A1 (fr) | 2008-03-17 | 2009-09-23 | AEterna Zentaris GmbH | Nouveaux dérivés de triazole 1,2,4 et leur processus de fabrication |
EP2293671A4 (fr) | 2008-06-03 | 2012-03-21 | Siga Technologies Inc | Inhibiteurs à petites molécules pour le traitement et la prévention de l'infection par le virus de la dengue |
AU2009266953A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Isoindolone derivatives as MEK kinase inhibitors and methods of use |
PE20110570A1 (es) | 2008-07-01 | 2011-08-26 | Genentech Inc | Heterociclos biciclicos sustituidos |
US20100031237A1 (en) | 2008-08-01 | 2010-02-04 | International Business Machines Corporation | Methods for Detecting Inter-Module Dependencies |
TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
DE102008038221A1 (de) | 2008-08-18 | 2010-02-25 | Merck Patent Gmbh | 7-Azaindolderivate |
WO2010062861A2 (fr) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Inhibiteurs de recyclage de l'acide biliaire pour le traitement de l'obésité et du diabète |
DE102008059702A1 (de) | 2008-12-01 | 2010-06-02 | Byk-Chemie Gmbh | Verfahren zur Herstellung rheologisch wirksamer Harnstoffurethane in organischen Salzen |
US8883827B2 (en) | 2009-06-05 | 2014-11-11 | Oslo University Hospital Hf | Azole derivatives as WTN pathway inhibitors |
KR101460095B1 (ko) | 2009-06-08 | 2014-11-10 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
US8846739B2 (en) | 2009-12-11 | 2014-09-30 | Exelixis Patent Company Llc | TGR5 agonists |
SG10201502484SA (en) | 2010-03-30 | 2015-05-28 | Verseon Corp | Multisubstituted aromatic compounds as inhibitors of thrombin |
US20130156755A1 (en) | 2010-04-19 | 2013-06-20 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor |
EP2560640A1 (fr) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr |
WO2011146801A1 (fr) | 2010-05-20 | 2011-11-24 | Synta Pharmaceuticals Corp. | Formulation et analyse de composés inhibiteurs de hsp90 |
EP3593802A3 (fr) | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Inhibiteurs de recyclage d'acide biliaire et satiogènes pour le traitement du diabète, de l'obésité et des conditions gastro-intestinales inflammatoires |
CN103140483B (zh) | 2010-07-15 | 2015-06-24 | 拜耳知识产权有限责任公司 | 作为杀虫剂的新杂环化合物 |
US20130266636A1 (en) | 2010-08-12 | 2013-10-10 | The Regents Of The University Of California | Methods for blocking cell proliferation and treating diseases and conditions responsive to cell growth inhibition |
WO2012027482A2 (fr) * | 2010-08-24 | 2012-03-01 | Georgetown University | Composés, compositions et méthodes associés aux antagonistes des ppar |
JP5517890B2 (ja) * | 2010-11-15 | 2014-06-11 | サンデン株式会社 | ショーケース及び照明モジュール |
CA2820800A1 (fr) * | 2010-12-08 | 2012-06-14 | Oslo University Hospital Hf | Derives de triazole en tant qu'inhibiteurs de la voie de signalisation wnt |
US20140045908A1 (en) | 2011-02-25 | 2014-02-13 | Synta Pharmaceuticals Corp. | Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers |
CA2842707A1 (fr) | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Inhibiteurs du recyclage de l'acide biliaire dans le traitement du pancreas |
US9593109B2 (en) | 2011-08-26 | 2017-03-14 | Cymabay Therapeutics, Inc. | Bicyclic agonists of GPR131 and uses thereof |
SG10201406155QA (en) | 2011-10-28 | 2014-11-27 | Lumena Pharmaceuticals Inc | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases |
MX369466B (es) | 2011-10-28 | 2019-11-08 | Lumena Pharmaceuticals Inc | Inhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas. |
JP2014534228A (ja) | 2011-11-02 | 2014-12-18 | シンタ ファーマシューティカルズ コーポレーション | 白金含有剤とhsp90阻害剤の組合せ療法 |
JP2014532712A (ja) | 2011-11-02 | 2014-12-08 | シンタ ファーマシューティカルズ コーポレーション | トポイソメラーゼi阻害剤とhsp90阻害剤の組合せを使用する癌療法 |
JP2014533299A (ja) | 2011-11-14 | 2014-12-11 | シンタ ファーマシューティカルズ コーポレーション | Braf阻害剤とhsp90阻害剤の組合せ療法 |
WO2013106437A1 (fr) | 2012-01-09 | 2013-07-18 | Anchor Therapeutics, Inc. | Composés de récepteurs apj |
EP2802577B1 (fr) | 2012-01-13 | 2017-03-01 | Bristol-Myers Squibb Company | Composés pyridyles à substitution triazolyle utiles comme inhibiteurs de kinases |
JP2015515469A (ja) | 2012-03-28 | 2015-05-28 | シンタ ファーマシューティカルズ コーポレーション | Hsp90阻害剤としてのトリアゾール誘導体 |
EP3409666A3 (fr) | 2012-06-07 | 2019-01-02 | Georgia State University Research Foundation, Inc. | Inhibiteurs de seca et leurs procédés de fabrication et d'utilisation |
US20140005181A1 (en) | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
SG11201501051UA (en) | 2012-09-21 | 2015-03-30 | Sanofi Sa | Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators |
JP6426107B2 (ja) | 2012-12-20 | 2018-11-21 | アムジエン・インコーポレーテツド | Apj受容体アゴニストおよびその使用 |
BR112015023294A2 (pt) | 2013-03-15 | 2017-07-18 | Shifa Biomedical Corp | método para tratamento ou prevenção de uma doença |
UY35517A (es) | 2013-04-04 | 2014-10-31 | Mabxience S A | Un procedimiento para aumentar la formación de ácido piroglutamico de una proteína |
JP6640716B2 (ja) | 2013-05-30 | 2020-02-05 | ワシントン・ユニバーシティWashington University | 細菌感染症を治療するための化合物及び方法 |
CA2942940A1 (fr) | 2014-03-20 | 2015-09-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Utilisation de composes inhibant la signalisation d'apeline/apj/gp130 pour le traitement du cancer |
JP6708556B2 (ja) | 2014-04-24 | 2020-06-10 | ナンヤン テクノロジカル ユニヴァーシティー | Asx特異的なタンパク質リガーゼ |
US10570128B2 (en) * | 2014-05-28 | 2020-02-25 | Sanford Burnham Prebys Medical Discovery Institute | Agonists of the apelin receptor and methods of use thereof |
BR112016028119A2 (pt) | 2014-06-06 | 2017-08-22 | Res Triangle Inst | Agonistas receptores de apelina (apj) e usos dos mesmos |
US20160058705A1 (en) | 2014-08-28 | 2016-03-03 | Jayakumar Rajadas | Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin |
MA42145B1 (fr) | 2015-05-20 | 2020-05-29 | Amgen Inc | Triazoles agonistes du récepteur apj |
EP3303330B1 (fr) | 2015-06-03 | 2019-05-01 | Bristol-Myers Squibb Company | Agonistes d'apj 4-hydroxy-3-(hétéroaryl)pyridine-2-one à utiliser dans le traitement de troubles cardio-vasculaires |
EP3115826A1 (fr) | 2015-07-06 | 2017-01-11 | Trumpf Laser Marking Systems AG | Dispositif pour la déviation d'un rayon laser |
WO2017010058A1 (fr) | 2015-07-14 | 2017-01-19 | パナソニックIpマネジメント株式会社 | Dispositif et procédé de reconnaissance de support d'identification |
PE20181197A1 (es) | 2015-10-14 | 2018-07-23 | Bristol Myers Squibb Co | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) |
WO2017091513A1 (fr) | 2015-11-24 | 2017-06-01 | Daiichi Sankyo Company, Limited | Nouveaux dérivés azolés comme agoniste du récepteur de l'apéline |
CN108473466B (zh) | 2015-12-04 | 2022-04-19 | 百时美施贵宝公司 | 爱帕琳肽受体激动剂及使用方法 |
RU2766148C1 (ru) | 2015-12-09 | 2022-02-08 | Рисерч Трайэнгл Инститьют | Улучшенные агонисты апелинового рецептора (apj) и их использование |
US9988369B2 (en) * | 2016-05-03 | 2018-06-05 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the APJ receptor |
-
2016
- 2016-05-18 MA MA42145A patent/MA42145B1/fr unknown
- 2016-05-18 UA UAA201712492A patent/UA119932C2/uk unknown
- 2016-05-18 WO PCT/US2016/033088 patent/WO2016187308A1/fr active Application Filing
- 2016-05-18 AU AU2016263564A patent/AU2016263564B2/en active Active
- 2016-05-18 US US15/158,174 patent/US9573936B2/en active Active
- 2016-05-18 BR BR112017024618-0A patent/BR112017024618B1/pt active IP Right Grant
- 2016-05-18 LT LTEP16730076.3T patent/LT3300500T/lt unknown
- 2016-05-18 SI SI201630732T patent/SI3300500T1/sl unknown
- 2016-05-18 PT PT167300763T patent/PT3300500T/pt unknown
- 2016-05-18 CN CN201680043275.0A patent/CN108137545B/zh active Active
- 2016-05-18 ES ES16730076T patent/ES2791315T3/es active Active
- 2016-05-18 EP EP16730076.3A patent/EP3300500B9/fr active Active
- 2016-05-18 HU HUE16730076A patent/HUE050317T2/hu unknown
- 2016-05-18 EA EA201792536A patent/EA034776B1/ru not_active IP Right Cessation
- 2016-05-18 PE PE2017002442A patent/PE20180529A1/es unknown
- 2016-05-18 DK DK16730076.3T patent/DK3300500T3/da active
- 2016-05-18 MX MX2017014818A patent/MX2017014818A/es unknown
- 2016-05-18 KR KR1020177036341A patent/KR102653667B1/ko active IP Right Grant
- 2016-05-18 ME MEP-2020-106A patent/ME03733B/fr unknown
- 2016-05-18 CA CA2985542A patent/CA2985542C/fr active Active
- 2016-05-18 RS RS20200613A patent/RS60353B1/sr unknown
- 2016-05-18 TN TNP/2017/000483A patent/TN2017000483A1/en unknown
- 2016-05-18 NZ NZ737004A patent/NZ737004A/en unknown
- 2016-05-18 PL PL16730076T patent/PL3300500T3/pl unknown
- 2016-05-18 JP JP2017560170A patent/JP6356364B1/ja active Active
- 2016-05-18 MY MYPI2017001685A patent/MY193818A/en unknown
- 2016-05-19 JO JOP/2016/0096A patent/JO3653B1/ar active
- 2016-05-20 UY UY0001036684A patent/UY36684A/es active IP Right Grant
- 2016-05-20 TW TW105115874A patent/TWI606039B/zh active
- 2016-05-20 AR ARP160101478A patent/AR104716A1/es unknown
- 2016-05-20 JP JP2016101104A patent/JP6055150B1/ja active Active
- 2016-10-19 US US15/297,487 patent/US9745286B2/en active Active
- 2016-10-19 US US15/297,272 patent/US9868721B2/en active Active
- 2016-10-19 US US15/297,940 patent/US9656997B2/en active Active
- 2016-10-20 US US15/298,686 patent/US9656998B2/en active Active
- 2016-10-20 US US15/298,434 patent/US9751864B2/en active Active
- 2016-10-20 US US15/298,748 patent/US9845310B2/en active Active
- 2016-11-30 JP JP2016232097A patent/JP6130964B2/ja active Active
-
2017
- 2017-06-21 US US15/629,567 patent/US10058550B2/en active Active
- 2017-11-06 IL IL255459A patent/IL255459A/en active IP Right Grant
- 2017-11-14 ZA ZA2017/07706A patent/ZA201707706B/en unknown
- 2017-11-17 CL CL2017002922A patent/CL2017002922A1/es unknown
- 2017-11-20 PH PH12017502107A patent/PH12017502107A1/en unknown
- 2017-12-18 CO CONC2017/0012991A patent/CO2017012991A2/es unknown
-
2018
- 2018-07-12 US US16/033,632 patent/US10221162B2/en active Active
- 2018-10-03 HK HK18112661.3A patent/HK1253366A1/zh unknown
- 2018-12-03 US US16/207,360 patent/US10344016B2/en active Active
-
2020
- 2020-04-29 HR HRP20200690TT patent/HRP20200690T1/hr unknown
- 2020-05-14 CY CY20201100442T patent/CY1123451T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42145B1 (fr) | Triazoles agonistes du récepteur apj | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA40123A1 (fr) | Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia | |
EA201991123A1 (ru) | ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV | |
MX2019005306A (es) | Compuestos mono y espirociclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v. | |
PH12020551062A1 (en) | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways | |
MA39554A3 (fr) | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock | |
EA201890318A1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
EA201991121A1 (ru) | АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV | |
MY199931A (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
MA35836B1 (fr) | 4 phényl-pyridines substituées pour le traitement de maladies associées à un récepteur nk-1 | |
CL2012000591A1 (es) | Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados. | |
MX2019005233A (es) | Pirrolamidas como inhibidores de la integrina alfa v. | |
MA41633B1 (fr) | Composés amide en tant qu'agonistes du récepteur 5-ht4 | |
MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
PH12020551734A1 (en) | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | |
MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
MA46462B1 (fr) | Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret | |
MA39533B1 (fr) | Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives | |
EA202090432A1 (ru) | Новые соединения, активирующие путь nrf2 | |
MA50899B1 (fr) | Composés utiles pour l'inhibition de cdk7 | |
MA41311B1 (fr) | Peptides antagonistes du cgrp | |
MA46625B1 (fr) | Inhibiteurs de lsd1 et leurs utilisations médicales | |
MA51146B1 (fr) | Composés hétérocycliques bicycliques substitués utilisés en tant qu'inhibiteurs de prmt5 |